Join the Atopic Dermatitis group to help and get support from people like you.
Atopic Dermatitis News (Page 2)
Related terms: Atopic Eczema, Dermatitis, Atopic, Discoid Eczema, Infantile Eczema
LEO Pharma Inc. Announces U.S. FDA Approval of Adbry (tralokinumab-ldrm) for the Treatment of Moderate-to-Severe Atopic Dermatitis in Pediatric Patients Aged 12-17 Years
Adbry is the first treatment for pediatric patients with moderate-to-severe atopic dermatitis specifically targeting the interleukin (IL)-13 cytokine, one of the key drivers of atopic dermatitis...
Updated Guidelines Released for Management of Atopic Dermatitis
THURSDAY, Dec. 28, 2023 – In updated guidelines issued by the American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology, and published online Dec. 17 in...
Recommendations Developed for Atopic Dermatitis Therapies
THURSDAY, Nov. 16, 2023 – In updated guidelines issued by the American Academy of Dermatology and published online Nov. 7 in the Journal of the American Academy of Dermatology, recommendations are...
Teens With Atopic Dermatitis More Likely to Experience Bullying
FRIDAY, Oct. 27, 2023 – Adolescents with versus those without atopic dermatitis (AD) have increased prevalence and frequency of experiencing bullying, according to a study published online Oct. 25...
Children With Eczema More Likely to Have Allergic Contact Dermatitis
MONDAY, Oct. 2, 2023 – Children with atopic dermatitis (AD) are more likely to have positive patch test (PPT) reactions, according to a study published online Sept. 25 in the Journal of the American...
Both Ciclosporin, Methotrexate Effective for Severe Eczema in Children
TUESDAY, Sept. 26, 2023 – For children and young people with severe atopic dermatitis (AD), ciclosporin (CyA) and methotrexate (MTX) are both effective over 36 weeks, according to a study published...
Atopic Dermatitis Increases Risk for Inflammatory Bowel Disease
THURSDAY, Aug. 31, 2023 – Both children and adults with atopic dermatitis have an increased risk for inflammatory bowel disease (IBD), according to a study published online Aug. 30 in JAMA...
Dupilumab Treatment Beneficial for Sleep in Atopic Dermatitis
TUESDAY, Aug. 22, 2023 – For adults with moderate-to-severe atopic dermatitis (AD), dupilumab treatment yields significant improvement in sleep quality and other AD-related signs and symptoms,...
Higher Risk for Schizophrenia Seen Among Patients With Eczema
TUESDAY, Aug. 8, 2023 – Having atopic dermatitis is associated with a higher risk for schizophrenia and schizoaffective disorder, according to a study published online July 26 in the Archives of...
FDA Approves Pfizer's Supplemental New Drug Application for Cibinqo (abrocitinib) to Include Adolescents with Moderate-to-Severe Atopic Dermatitis
Label expansion for Cibinqo provides new systemic oral option for adolescents (12 to
FDA Approves Dupixent (dupilumab) as First Biologic Medicine for Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis
Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood Children treated with Dupixent and topical corticosteroids (TCS)...
FDA Approves Cibinqo (abrocitinib) for Adults with Moderate-to-Severe Atopic Dermatitis
NEW YORK--(BUSINESS WIRE) January 14, 2022 – Pfizer Inc. (NYSE: PFE) announced today that the United States (U.S.) Food and Drug Administration (FDA) approved Cibinqo® (abrocitinib), an oral, ...
FDA Approves Adbry (tralokinumab-ldrm) for Adults with Moderate-to-Severe Atopic Dermatitis
MADISON, N.J.--(BUSINESS WIRE) December 28, 2021 --LEO Pharma Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Adbry™ (tralokinumab-ldrm) for the treatment of m...
FDA Approves Opzelura (ruxolitinib) Cream for the Treatment of Atopic Dermatitis (AD)
WILMINGTON, Del.--(BUSINESS WIRE) September 21, 2021 – Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Opzelura™ (ruxolitinib) cream for the s...
FDA Approves Dupixent (dupilumab) as First Biologic Medicine for Children Aged 6 to 11 Years with Moderate-to-Severe Atopic Dermatitis
TARRYTOWN, N.Y. and PARIS, May 26, 2020 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupi...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Related drug support groups
prednisone, methylprednisolone, clobetasol, fluocinonide, Dupixent, dexamethasone, desonide, halobetasol